MANE · Veradermics Inc
Price
Snapshot
50 fields · last close| Market Cap | $4.12B |
| P/E | — |
| Float | 38.43M |
| Beta | -0.14 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 60 |
| Price | 98.51 |
| Change | +0.00% |
| Prev Close | 98.51 |
| Open | 98.92 |
| Day Low | 97.20 |
| Day High | 99.89 |
| Avg Vol | 1 |
| Avg $ Vol | $53.50M |
| 52W High | 131.24 |
| 52W Low | 32.00 |
| 52W Pos | 67.0% |
| From High | −24.94% |
| From Low | +207.84% |
| Max DD 1Y | −24.84% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −5.52% |
| SMA 50 | −10.68% |
| SMA 200 | — |
| RSI (14) | 41.3 |
| Vol 30D | 45.1% |
| Vol 90D | 70.3% |
| 1Y Range | 32–131 |
| Daily bars | 148 |
| Perf Week | +0.59% |
| Perf Month | −9.33% |
| Perf Quarter | +7.44% |
| Perf Half Y | +102.86% |
| Perf Year | — |
| Perf YTD | +160.95% |
| Prev Day | +0.00% |
| Clavix | D- |
| Debt / Eq | 0.00 |
| Curr Ratio | 16.66 |
| Int Cover | -253.7× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Low |
| Sector rank | 13 / 15 |
Clavix risk grade
regraded every trading dayMANE grades D-, 60 of 100. Steadiest on Sector Resilience (69), most exposed on Price Stability (39, fragile). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 13 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| MANE | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | −0.14 | 0.43 |
| Volatilityannualized | 5.0% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −24.8% | — |
| Typical daily movemedian absolute daily change | 3.05% | — |
| Days beyond ±3%of the last 147 sessions | 7652% | — |
How its days are spread
Daily returns over the last 147 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MANE | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | −0.14 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MANE | |
|---|---|
| 1 week | +0.6% |
| 1 month | −9.3% |
| Year to date | +161.0% |
| 1 year | — |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MANE | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 16since 21 May |
| Average score0 most bearish, 100 most bullish | 54 |
| Bullish · bearisharticles above 60 · below 40 | 7 · 5 |
| Directionarticles whose tone is improving vs worsening | 7 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| MANE | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | MANE | Sector spread | Median |
|---|---|---|---|
| Beta | -0.14 | 0.43 | |
| Volatility | 5.0% | 10.7% | |
| Debt / equity | 0.00 | 0.94 | |
| Current ratio | 16.66 | 1.86 | |
| Interest coverage | -253.7× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openThe author says standard valuation comparison ratios, like share price relative to sales and share price relative to earnings, show the stock as stretched, while broader measures that factor in growth and profitability give mixed readings.
A director of Veradermics (MANE), Montanova Capital LLC, sold 750,000 shares on August 19th at an average price of $107.25, totaling about $80.4 million. After the sale, the director still owned 461,033 shares worth roughly $49.4 million, meaning they cut their stake by about 62%.
An insider at Veradermics (ticker MANE), Timothy August Durso, sold 43,500 shares on August 17 at an average price of $107.82, totaling about $4.69 million and cutting his stake by roughly 36%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which is a schedule insiders set up in advance to buy or sell shares on specific dates.
Veradermics (NYSE: MANE) reported Q2 2026 financial results and highlighted progress in developing VDPHL01, a therapeutic for female pattern hair loss, with advancements supporting key clinical milestones during the quarter.
Baron Capital's Q2 2026 investor letter highlighted Veradermics (MANE) as a company positioned to disrupt the hair loss market. The Baron Health Care Fund gained 11.99% during the quarter, outperforming the Russell 3000 Health Care Index's 10.48% gain but underperforming the Russell 3000 Index's 15.44% gain.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals Inc | D+ | $9.01B | — | 0.45 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $10.83B | — | 0.81 | Compare |
| CORT | Corcept Therapeutics Inc | C- | $12.07B | 218.66 | 0.50 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.24B | — | 1.76 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $16.02B | 17.03 | 0.37 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.92 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.97 | 0.69 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.78B | 45.13 | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.